NervGen Pharma Corp. has announced the appointment of Dr. Sam Jackson as its new Chief Medical Officer, effective December 7, 2026. This strategic move is aimed at strengthening the company’s clinical development capabilities in the competitive pharmaceutical preparations sector.
Dr. Jackson brings over 20 years of experience in leading clinical development for various neurological and immunological programs. His previous roles include serving as the Chief Medical Officer at Aditum Bio and Neuron23 Inc., where he was instrumental in managing clinical strategies and operations.
Background
NervGen Pharma Corp. operates in the pharmaceutical preparations industry, focusing on innovative treatments for neurological disorders. The company trades under the ticker symbol NGEN on the Nasdaq. It is categorized as an emerging growth company, reflecting its commitment to developing novel therapeutic solutions.
What the Filing Says
According to the filing dated November 18, 2026, Dr. Jackson will report directly to the Chief Executive Officer and will be responsible for overseeing the company’s clinical development strategy, particularly the NVG-291 program and the Phase 3 RESTORE study. The filing states, "Dr. Jackson will be paid an annualized base salary of $525,000 and is eligible for a bonus based on performance objectives." Additionally, he will receive stock options to purchase up to 1,156,135 common shares of the company.
Impact
This appointment is expected to impact various stakeholders, including investors, employees, and patients seeking innovative treatments. Dr. Jackson's expertise may enhance NervGen's ability to advance its clinical trials and regulatory strategies, which could lead to significant developments in the treatment of neurological conditions.
What's Next
The filing does not specify what happens next, but Dr. Jackson's start date is set for December 7, 2026, and he will begin to implement the company's clinical development strategies immediately thereafter.
Read Next
Cloudflare's Michelle Zatlyn Sells Over $1.5M in Shares
Zurn Elkay VP LaMotte Jeremy L Reports Stock Sale
XTI Aerospace CEO Jeremy Schneiderman Reports Stock Exchange
Jennifer Salinas acquires 366,529 shares in Cerence Inc.
Mentz Christian acquires 125,979 shares of Cerence Inc.
Cerence CEO Acquires 819,039 Shares in Stock Transaction










